Division of Gedeon Richter PLC
Latest From PregLem SA
Venture capitalists tell START-UP’s annual survey that seeing will be believing when it comes to the potential of single-asset models. Plus news on recent financings by iPierian, Evotec, ObsEva and Acacia.
Swiss specialty biopharma start-up ObsEva has banked a CHF32m (€25.6m) series A financing, which it plans to use to develop a batch of compounds that it has concurrently licensed from Merck Serono.
The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.
Bayer, one of the world’s largest women’s health firms, is looking East and South for growth in its women’s health franchise, shifting its attention away from mature markets in the U.S. and Europe.
- Large Molecule
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Western Europe
- Parent & Subsidiaries
- Gedeon Richter PLC
- Senior Management
Ksenija Pavletic Aranicki, CEO
Jean-Pierre Nkurunziza, Fin. Dir.
Pablo Arriagada, MD, VP, Medical Affairs
Vilma Durante, VP, Global Mktg.
- Contact Info
Phone: (41) 22 884 0350
Route de Frontenex 41A
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.